

Bactover

Mupirocin BP 2%

Composition

Bactover ointment: Each gram ointment contains Mupirocin BP 20 mg.

Pharmacology

Mupirocin is a naturally occurring antibiotic. It is an antibacterial agent produced by fermentation using the organism *Pseudomonas fluorescens*. It is active against a wide range of bacteria those responsible for the majority of skin infections, e.g. *Staphylococcus aureus* including methicillin-resistant *Staphylococcus aureus* (MRSA) other staphylococci and streptococci. It is also active against certain gram-negative pathogens, like *Escherichia coli* and *Haemophilus influenzae*. Mupirocin inhibits bacterial protein synthesis by reversibly and specifically binding to bacterial isoleucyl transfer-RNA synthetase. Due to this unique mode of action, mupirocin demonstrates no in vitro cross-resistance with other classes of antimicrobial agents. Mupirocin is bactericidal at concentrations achieved by topical administration. However, the minimum bactericidal concentration (MBC) against relevant pathogens is generally eight-fold to thirty-fold higher than the minimum inhibitory concentration (MIC).

Indication

Bactover ointment is indicated for the topical treatment of impetigo due to: *Staphylococcus aureus* and *Streptococcus pyogenes*.

Dosage and Administration

A small amount of Bactover ointment should be applied to the affected area three times daily. The area treated may be covered with gauze dressing if desired. Patients not showing a clinical response within 3 to 5 days should be re-evaluated.

Contraindication

This drug is contraindicated in individuals with a history of sensitivity reactions to any of its components.

Warning and Precaution

Mupirocin ointment is not for ophthalmic or intra-nasal use. If a reaction suggesting sensitivity or chemical

irritation should occur with the use of Mupirocin ointment, treatment should be discontinued and appropriate alternative therapy for the infection instituted. As with other antibacterial products, prolonged use may result in overgrowth of nonsusceptible organisms, including fungi. When Mupirocin is used on the face care should be taken to avoid the eyes. Polyethylene Glycol can be absorbed from open wounds and damaged skin and is secreted by the kidneys. In common with other polyethylene glycol-based ointments, Mupirocin ointment should not be used in conditions where absorption of large quantities of polyethylene glycol is possible, especially if there is evidence of moderate or severe renal impairment.

Side effects

The following local adverse reactions have been reported in connection with the use of Mupirocin ointment: burning, stinging, or pain in 1.5% of patients; itching in 1% of patients; rash, nausea, erythema, dry skin, tenderness, swelling, contact dermatitis, and increased exudate in less than 1% of patients.

Use in Pregnancy & Lactation

The drug is classified in Pregnancy Category B. Because animal studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Mupirocin is used to a nursing woman.

Drug interaction

The effect of the concurrent application of Mupirocin and other drug products has not been studied.

Storage

Store below 25°C in a dry place, away from light. Keep out of the reach of children.

Packaging

Bactover ointment: Each pack has a laminated tube containing 10 gm ointment.

Manufactured By

BEACON[®]

Pharmaceuticals PLC

Bhaluka, Mymensingh, Bangladesh